Table 4 Genotypic distribution and allele frequency of rs4910623, rs323085 and rs10158937 and association with VA response at six and three months of anti-VEGF treatment in the replication cohort.

From: GWAS study using DNA pooling strategy identifies association of variant rs4910623 in OR52B4 gene with anti-VEGF treatment response in age-related macular degeneration

6 Month++

SNP

A1

A2

Genotype frequency*

Allele frequency+

P-Value

OR 95% CI

Responders

Non-responders

Responders

Non-Responders

rs4910623

G

A

0.24/0.48/0.28

0.34/0.54/0.12

0.48/0.52

0.62/0.38

3.5 × 10 −2

1.71 (1.04–2.80)

rs323085

C

T

0.02/0.25/0.74

0.00/0.21/0.79

0.14/0.86

0.10/0.90

0.46

0.74 (0.34–1.63)

rs10158937

C

A

0.05/0.32/0.63

0.02/0.30/0.67

0.21/0.79

0.17/0.83

0.58

0.84 (0.45–1.57)

3 Month

rs4910623

G

A

0.22/0.50/0.28

0.39/0.46/0.15

0.47/0.53

0.62/0.38

2.4 × 10 −3

1.83 (1.24–2.71)

rs323085

C

T

0.03/0.24/0.73

0/0.23/0.77

0.15/0.85

0.11/0.89

0.34

0.74 (0.50–1.33)

rs10158937

C

A

0.04/0.32/0.64

0.06/0.35/0.59

0.20/0.80

0.23/0.77

0.25

1.31 (0.83–2.06)

  1. Definition of response was the same as in the pooled GWAS: Non-responders are patients who have lost ≥5 ETDRS letters and the remainder were classified as responders P-Value: Calculated using logistic regression adjusted for baseline visual acuity and age, OR = odd ratio, representing trend per copy effect of risk or minor allele on VA outcome, highlighted in bold for each SNP, CI: Confidence Interval, *Genotype frequency A1A1/A1A2/A2A2, +Allele frequency A1/A2. ++In replication cohort pro re nata treated patients included n = 215.
Back to article page